Novartis: Cosentyx misses endpoint in head-to-head trial

(CercleFinance.com) - Novartis said that its drug Cosentyx has failed to meet the primary endpoint in a head-to-head trial comparing it to AbbVie's Humira in patients with active psoriatic arthritis.


Cosentyx narrowly missed statistical significance for superiority in ACR20, a composite measure defined as an improvement of 20% in the disease's main symptoms, the Swiss drugmaker said.

However, the drug showed numerically higher results versus Humira, and statistically significant advantages versus AbbVie's drug in specific endpoints, Novartis said.

The shares were trading down slightly (-0.1%) in Zurich on Friday morning.

Copyright (c) 2019 CercleFinance.com. All rights reserved.